Use of pegylated interferon in children with chronic hepatitis B and C: the Geneva and Lausanne experience
Détails
ID Serval
serval:BIB_F75335C85BC1
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Use of pegylated interferon in children with chronic hepatitis B and C: the Geneva and Lausanne experience
Titre de la conférence
Annual meeting of the Swiss Society for Pediatrics
Adresse
St. Gall (Switzerland), June 18-20, 2009
ISBN
1424-7860
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
139
Série
Swiss Medical Weekly
Pages
4S
Langue
anglais
Notes
Aims: Hepatitis B and C cause morbidity and mortality. Vertical infection is the most important route of transmission in children and long-term spontaneous clearance is known to be low. Children with active disease who are at high risk to develop cirrhosis and hepatocarcinoma were treated in our divisions.
Methods: HBV and HCV groups received for 48 weeks subcutaneous
recombinant peginterferon alfa-2a (Pegasys®) at a dosage of 100 μg/m2
once per week in combination with oral ribavirin (15 mg/kg x day in 2 doses) for the HCV group. Physical examinations, viral load, ALT levels and blood count were determined during the treatment and the follow-up (3 and 6 months after the end of the treatment).
Results: HBV group: 15 patients, median age 12,5 y (4-17 y), 4 horizontal, 10 unknown and 1 sexual transmissions, all HBsAg/HBeAg positive. 5/9 had HBeAg seroconversion with one concomitant HBsAg seroconversion, 4 did not have seroconversion, 2 discontinued therapy after 12 weeks because of elevated transaminase or no response to treatment, 4 are still on therapy. HCV group: 10 patients, median age 7y (3-15 y), 8 vertical, 2 unknown transmissions. 5 genotypes 1A, 2 genotypes 1B, 3 genotypes 3A, 7/10 had negative viremia after 24 weeks of treatment (early viral response), 2 are still on therapy, 1 stopped the therapy after 36 weeks because of no response (genotype 1A). At present, no negative viremia at 24 weeks relapsed in the follow-up period.
Conclusion: Our patients tolerated well the therapy with minor side effects. Weekly peginterferon was well accepted even in very young children. We had 5/15 HBeAg seroconversion with one HBsAg seroconversion and 7/10 early viral response with hepatitis C. In the literature, 1/3 of children with hepatitis B have a sustained response to therapy and 1/10 will become both HBeAg and HBsAg negative. In hepatitis C, between 44 and 75% will have sustained viral response according to the genotype. Therefore, in our hands, both HBV and HCV therapies seem to be more effective than reported in the literature, certainly due to precocious intervention.
Methods: HBV and HCV groups received for 48 weeks subcutaneous
recombinant peginterferon alfa-2a (Pegasys®) at a dosage of 100 μg/m2
once per week in combination with oral ribavirin (15 mg/kg x day in 2 doses) for the HCV group. Physical examinations, viral load, ALT levels and blood count were determined during the treatment and the follow-up (3 and 6 months after the end of the treatment).
Results: HBV group: 15 patients, median age 12,5 y (4-17 y), 4 horizontal, 10 unknown and 1 sexual transmissions, all HBsAg/HBeAg positive. 5/9 had HBeAg seroconversion with one concomitant HBsAg seroconversion, 4 did not have seroconversion, 2 discontinued therapy after 12 weeks because of elevated transaminase or no response to treatment, 4 are still on therapy. HCV group: 10 patients, median age 7y (3-15 y), 8 vertical, 2 unknown transmissions. 5 genotypes 1A, 2 genotypes 1B, 3 genotypes 3A, 7/10 had negative viremia after 24 weeks of treatment (early viral response), 2 are still on therapy, 1 stopped the therapy after 36 weeks because of no response (genotype 1A). At present, no negative viremia at 24 weeks relapsed in the follow-up period.
Conclusion: Our patients tolerated well the therapy with minor side effects. Weekly peginterferon was well accepted even in very young children. We had 5/15 HBeAg seroconversion with one HBsAg seroconversion and 7/10 early viral response with hepatitis C. In the literature, 1/3 of children with hepatitis B have a sustained response to therapy and 1/10 will become both HBeAg and HBsAg negative. In hepatitis C, between 44 and 75% will have sustained viral response according to the genotype. Therefore, in our hands, both HBV and HCV therapies seem to be more effective than reported in the literature, certainly due to precocious intervention.
Site de l'éditeur
Création de la notice
29/01/2010 18:45
Dernière modification de la notice
20/08/2019 17:23
Données d'usage
